Donald E Kohan - JoVE Visualize

Showing results (151-160 of 153) with videos related to

Pageof 16

Sort By:

You have reached the last page of results.This site can display upto 153 results.

Clinical Pharmacology and Therapeutics|July 27, 2022

Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney DiseaseJ David Smeijer, Jeroen V Koomen, Donald E Kohan, et al.

Lancet (London, England)|June 4, 2026

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trialHiddo J L Heerspink, Meg J Jardine, Donald E Kohan, et al.

Lancet (London, England)|November 6, 2023

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialBrad H Rovin, Jonathan Barratt, Hiddo J L Heerspink, et al.

Pageof 16

Showing results (151-160 of 153) with videos related to

Sort By:

Pageof 16

You have reached the last page of results.This site can display upto 153 results.

Clinical Pharmacology and Therapeutics|July 27, 2022

Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney DiseaseJ David Smeijer, Jeroen V Koomen, Donald E Kohan, et al.

Lancet (London, England)|June 4, 2026

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trialHiddo J L Heerspink, Meg J Jardine, Donald E Kohan, et al.

Lancet (London, England)|November 6, 2023

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialBrad H Rovin, Jonathan Barratt, Hiddo J L Heerspink, et al.

Pageof 16